Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction (EXAMI): Study protocol for a randomized controlled trial
Trials, ISSN: 1745-6215, Vol: 12, Issue: 1, Page: 240
2011
- 17Citations
- 62Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations17
- Citation Indexes17
- 17
- CrossRef15
- Captures62
- Readers62
- 62
Article Description
Background: Myocardial infarction causes irreversible loss of cardiomyocytes and may lead to loss of ventricular function, morbidity and mortality. Infarct size is a major prognostic factor and reduction of infarct size has therefore been an important objective of strategies to improve outcomes. In experimental studies, glucagon-like peptide 1 and exenatide, a long acting glucagon-like peptide 1 receptor agonist, a novel drug introduced for the treatment of type 2 diabetes, reduced infarct size after myocardial infarction by activating pro-survival pathways and by increasing metabolic efficiency.Methods: The EXAMI trial is a multi-center, prospective, randomized, placebo controlled trial, designed to evaluate clinical outcome of exenatide infusion on top of standard treatment, in patients with an acute myocardial infarction, successfully treated with primary percutaneous coronary intervention. A total of 108 patients will be randomized to exenatide (5 μg bolus in 30 minutes followed by continuous infusion of 20 μg/24 h for 72 h) or placebo treatment. The primary end point of the study is myocardial infarct size (measured using magnetic resonance imaging with delayed enhancement at 4 months) as a percentage of the area at risk (measured using T2 weighted images at 3-7 days).Discussion: If the current study demonstrates cardioprotective effects, exenatide may constitute a novel therapeutic option to reduce infarct size and preserve cardiac function in adjunction to reperfusion therapy in patients with acute myocardial infarction.Trial registration: ClinicalTrials.gov: NCT01254123. © 2011 Scholte et al; licensee BioMed Central Ltd.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=80455158258&origin=inward; http://dx.doi.org/10.1186/1745-6215-12-240; https://clinicaltrials.gov/ct2/show/NCT01254123; http://www.ncbi.nlm.nih.gov/pubmed/22067476; https://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-12-240; https://dx.doi.org/10.1186/1745-6215-12-240; http://link.springer.com/article/10.1186/1745-6215-12-240/fulltext.html; https://link.springer.com/track/pdf/10.1186/1745-6215-12-240; https://link.springer.com/articles/10.1186/1745-6215-12-240; https://link.springer.com/article/10.1186/1745-6215-12-240; http://www.trialsjournal.com/content/12/1/240; https://trialsjournal.biomedcentral.com/counter/pdf/10.1186/1745-6215-12-240; http://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-12-240
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know